Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of cendakimab in eosinophilic esophagitis
2020-004335-24Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cendakimab in eosinophilic esophagitis (EoE), sponsored by Celgene Corporation. Primary endpoint: Long-term safety and tolerability. Started Jul 2021; status: active.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2020-004335-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004335-24.